# US 2013/0253181 A1 · Methods of preparing substituted nucleotide analogs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0253181 A1
- Document ID: US20130253181A1
- Status: Published application
- Kind: A1
- Application number: 13/793,900
- Filed: 2013-03-11
- Published: 2013-09-26
- Earliest claimed: 2012-03-21
- Assignees: Vertex Pharmaceuticals Incorporated; Alios BioPharma, Inc.
- Applicants: Alios Biopharma, Inc.; Vertex Pharmaceuticals Inc.
- Inventors: Vladimir Serebryany; Jyanwei Liu; Leonid Beigelman; Young Chun Jung
- Web page: https://patentgrep.com/patent/US20130253181A1

## CPC

- C07H 19/10: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- A61P 31/12: Antivirals
- C07F 9/26: containing P-halide groups
- C07F 9/6506: having the nitrogen atoms in positions 1 and 3
- C07F 9/65586: {at least one of the hetero rings does not contain nitrogen as ring hetero atom}
- C07H 1/00: Processes for the preparation of sugar derivatives
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Disclosed herein are methods of preparing a phosphorothioate nucleotide analog, which are useful in treating diseases and/or conditions such as viral infections.

## Claims

### Claim 1

A method of preparing a compound of Formula (I):
wherein the method comprises:
coupling a compound of Formula (A) and a compound of Formula (B), wherein the —OH groups and —NH group of the compound of Formula (A) are unprotected during the coupling reaction.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) comprises a diastereomeric mixture of a compound of Formula (I)(i) and a compound of Formula (I)(ii),

### Claim 3 (depends on 1)

The method of claim 1, wherein the coupling is performed in the presence of a base, an acid or a Grignard reagent.

### Claim 4 (depends on 3)

The method of claim 3, wherein the base is an optionally substituted amine base, an optionally substituted pyridine, or an optionally substituted imidazole.

### Claim 5 (depends on 4)

The method of claim 4, wherein the optionally substituted pyridine is collidine.

### Claim 6 (depends on 4)

The method of claim 4, wherein the optionally substituted imidazole is N-methylimidazole.

### Claim 7 (depends on 1)

The method of claim 1, wherein the coupling is conducted in a polar aprotic solvent.

### Claim 8 (depends on 7)

The method of claim 7, wherein the polar aprotic solvent is acetonitrile.

### Claim 9 (depends on 7)

The method of claim 7, wherein the polar aprotic solvent is methyl isobutyl ketone.

### Claim 10 (depends on 1)

The method of claim 1, wherein the compound of Formula (B) is present in excess by molarity compared to the compound of Formula (A).

### Claim 11 (depends on 10)

The method of claim 10, wherein a molar ratio of the compound of Formula (B) to the compound of Formula (A) in the coupling reaction is at least 1.15 eq.:1.0 eq.

### Claim 12 (depends on 10)

The method of claim 10, wherein a molar ratio of the compound of Formula (B) to the compound of Formula (A) in the coupling reaction is in the range of 1.3 eq. to 1.6 eq.:1 eq.

### Claim 13 (depends on 2)

The method of claim 2, wherein the mixture of the compound of Formula (I)(i) and the compound of Formula (I)(ii) is diastereomerically enriched in the compound of Formula (I)(ii).

### Claim 14 (depends on 2)

The method of claim 2, wherein the mixture of the compound of Formula (I)(i) and the compound of Formula (I)(ii) is a diastereomeric mixture with a diastereomeric ratio of 1:1.5 or more of the compound of Formula (I)(i) to the compound of Formula (I)(ii).

### Claim 15 (depends on 2)

The method of claim 2, wherein the mixture of the compound of Formula (I)(i) and the compound of Formula (I)(ii) is a diastereomeric mixture with a diastereomeric ratio of 1:1.7 or more of the compound of Formula (I)(i) to the compound of Formula (I)(ii).

### Claim 16 (depends on 2)

The method of claim 2, wherein the mixture of the compound of Formula (I)(i) and the compound of Formula (I)(ii) is a diastereomeric mixture with a diastereomeric ratio of 1:2.0 or more of the compound of Formula (I)(i) to the compound of Formula (I)(ii).

### Claim 17 (depends on 1)

The method of claim 1, further comprising:
(i) combining the compound of Formula (I) and isopropylacetate;
(ii) conducting a first crystallization that comprises tert-butyl methyl ether; and
(iii) optionally, conducting a second crystallization that comprises tert-butyl methyl ether.

### Claim 18 (depends on 1)

The method of claim 1, further comprising:
(i) conducting a first crystallization that comprises tert-butyl methyl ether; and
(ii) optionally, a second recrystallization that comprises tert-butyl methyl ether.

### Claim 19 (depends on 1)

The method of claim 1, further comprising:
(i) combining the compound of Formula (I) and ethyl acetate;
(ii) conducting a first crystallization that comprises tert-butyl methyl ether; and
(iii) optionally, conducting a second crystallization that comprises tert-butyl methyl ether.

### Claim 20 (depends on 1)

The method of claim 1, wherein the obtained compound of Formula (I) is diastereomerically enriched in the compound of Formula (I)(ii).

### Claim 21 (depends on 20)

The method of claim 20, wherein the obtained compound of Formula (I)(ii) is diastereometrically enriched by >90% (eq. of the compound of Formula (I)(ii)/(total eq. of the compound Formula (I)(i)+total eq. of the compound of Formula (I)(ii)).

### Claim 22 (depends on 20)

The method of claim 20, wherein the obtained compound of Formula (I)(ii) is diastereometrically enriched by >98% (eq. of the compound of Formula (I)(ii)/(total eq. of the compound Formula (I)(i)+total eq. of the compound of Formula (I)(ii)).

### Claim 23 (depends on 1)

The method of claim 1, further comprising separating a portion of the compound of Formula (I)(i) from the diastereomeric mixture of a compound of Formula (I)(i) and a compound of Formula (I)(ii) by supercritical fluid chromatography.

### Claim 24 (depends on 1)

The method of claim 1, further comprising separating a portion of the compound of Formula (I)(i) from the diastereomeric mixture of a compound of Formula (I)(i) and a compound of Formula (I)(ii) by recrystallization.

### Claim 25

A method of preparing a compound of Formula (B) comprising:
reacting O-phenylphosphorodichloridothioate with (S)-isopropyl 2-aminopropanote methanesulfonic acid.
